Radiation Oncology, Treatment Protocols
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
As of February 12, 2018 Arm 2 is permanently closed having met its enrollment goal.
The NRG-GI002 study serves as a platform to test novel agents in the neoadjuvant treatment of rectal cancer. It is projected that enrollment to the ARM1 (control) vs. ARM 3 (MK-3475/pembrolizumab) comparison could meet the accrual goal of 178 patients as early as May 13, 2019. The pembrolizumab comparison will complete enrollment before activation of another experimental arm. This will result in a temporary suspension of accrual to the entire NRG-GI002 trial.
As of Tuesday, May 14th, 2019 at 9:00 am EST, NRG-GI002 (Arm 1 and 3) has met its accrual goal and is temporarily suspended.